GLP-1s and birth control: what actually changes on the pill.

The difference is on the labels themselves: the FDA label for Zepbound (tirzepatide) carries the four-week contraception instruction in its drug-interaction section, while the label for Wegovy (semaglutide) reports no clinically significant effect on ethinyl estradiol or levonorgestrel. If you have not chosen between the two yet, the free GLP-1 cost calculator is a reasonable place to start the comparison.

Most women who start a GLP-1 are already managing one other daily medication, and for a lot of them it is the pill. The question comes up early — usually around week two, usually at night — and the answer online is a mess, because most of what is written about it treats semaglutide and tirzepatide as interchangeable. On this subject they are not.

This is the full picture: which medication affects the pill, by how much, for how long, what to do about it, which methods are unaffected, and what the labels say about pregnancy and breastfeeding. It is written for women, though the pregnancy section applies to anyone planning a family while on treatment.

Standard caveat, which matters more than usual here: this is a summary of what the FDA labels and the manufacturers say. Your prescriber and whoever manages your contraception are the people who decide what applies to you.

Does semaglutide affect birth control?

According to its FDA label, no — not in a way that matters clinically. The Wegovy label reports that giving semaglutide alongside a combined pill did not produce clinically significant differences in the blood levels of ethinyl estradiol or levonorgestrel, the two hormones in most combination pills. There is no contraception-specific instruction in the label's drug-interaction section.

That said, semaglutide does slow gastric emptying, which is the mechanism that can change how any oral medication is absorbed. The label asks clinicians to keep an eye on oral medications that need precise levels, and it specifically documents a change in levothyroxine exposure. So the honest summary is: the pill was tested, the numbers did not move meaningfully, and no backup method is required by the label. If you vomit within a couple of hours of taking your pill — which is more likely in the first weeks on a GLP-1 — your pill's own missed-dose rules apply, and those are worth rereading.

Does tirzepatide affect birth control?

Yes, and the label is direct about it. The Zepbound drug-interaction section says patients using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for four weeks after starting tirzepatide and for four weeks after each dose escalation. Hormonal methods that are not taken by mouth are not affected.

The numbers behind that instruction come from a study of a single tirzepatide dose given with a combination pill. Peak levels of ethinyl estradiol dropped by about 59 percent, and the time to reach peak was delayed by several hours. Total exposure of ethinyl estradiol over the day fell by around 20 percent. Those are not small changes for a medication whose job depends on steady hormone levels.

The reason the instruction is tied to the start and to each dose increase, rather than to the whole course of treatment, is that the slowing of the stomach is strongest after a new dose and settles as the body adjusts. The manufacturer's own guidance says the effect is largest after the first dose and diminishes over time. That is why the window is four weeks, repeated at each step up, rather than permanent.

Why the two medications differ

Both drugs slow gastric emptying. Tirzepatide acts on two receptors — GLP-1 and GIP — and its effect on stomach transit after a new dose appears to be larger, which is the plausible explanation for why the pill's absorption drops more. The practical point is not the pharmacology. It is that one label carries an instruction and the other does not, and the instruction is the thing to follow.

If you are still deciding between them, this is one of the few concrete differences in day-to-day use, and it is worth weighing alongside the ones in our tirzepatide vs semaglutide comparison.

What counts as a non-oral method

Anything that does not pass through your stomach. A hormonal IUD, a copper IUD, the implant, the vaginal ring, the patch, and the injection all deliver hormone — or in the copper IUD's case, no hormone — without relying on absorption from the gut, and the Zepbound label states that non-oral hormonal methods should not be affected. Condoms are the barrier method the label refers to when it says "add a barrier."

If you are on the pill and starting tirzepatide, the simplest options are: use condoms for the four weeks after you start and the four weeks after each increase, or talk to whoever manages your contraception about switching to a longer-acting method before you begin. The second option removes the question for the rest of treatment.

If you are on the pill and starting tirzepatide

Map the dose schedule before the first injection. Tirzepatide is typically escalated every four weeks through several steps, and each step restarts the four-week backup window. In practice that can mean backup contraception for most of the first several months of treatment — which is the point at which most women decide a long-acting method is less hassle than tracking windows on a calendar.

Keep taking the pill as normal; the instruction is to add backup or switch, not to stop. Tell your prescriber what method you use so it is in the record. And if your clinician delays an escalation because the previous dose was not tolerated well — the label allows a four-week delay for that — the backup window follows the actual dose change, not the planned date.

Pregnancy: stop before you try

Both labels say the same thing in different words. Weight loss offers no benefit during pregnancy and may cause harm to the fetus, and both medications should be stopped as soon as a pregnancy is recognized. The Wegovy label goes further on planning: because semaglutide clears from the body slowly, it says to discontinue at least two months before a planned pregnancy. Tirzepatide's label does not specify a lead time but carries the same instruction to stop when pregnancy is recognized.

For anyone hoping to conceive in the next year, this is a conversation to have before starting rather than after. A GLP-1 can be part of a plan that includes a pause before trying; it should not be a surprise to your prescriber six months in.

Breastfeeding

The evidence is thin and the labels say so. For tirzepatide, a small study found concentrations in breast milk that were either undetectable or very low — cumulatively under 0.02 percent of the mother's dose — but there are no data on effects in a breastfed infant or on milk production. For semaglutide, the label states there are no data on its presence in human milk. Neither is a green light. Both are a reason to involve your clinician and your child's pediatrician in the decision rather than reading a label and guessing.

Nausea, vomiting, and the pill

Nausea is the most common side effect of both medications — 44 percent of adults on Wegovy reported it in the trials, and vomiting was reported by 24 percent. Most of that lands in the first weeks and around each dose increase. If you vomit within a few hours of taking a pill, it may not have been absorbed, and your pill's leaflet will have a rule for that — usually to treat it as a missed pill. This is true on either GLP-1 and is separate from the tirzepatide interaction above. Our guide to eating on a GLP-1 covers the food choices that make nausea less likely in the first place.

When to talk to a clinician

Talk to a clinician before starting if you rely on the pill, if you are planning a pregnancy within the next year, if you are breastfeeding, or if you have a condition like PCOS where the two decisions overlap. Talk to one during treatment if you have had repeated vomiting, if you have missed pills, or if you are unsure whether a backup window applies to a dose change your clinician made. At Maro, contraception and pregnancy plans are part of the written intake before any prescription is issued, and the GLP-1 page explains how the review works.

Frequently asked questions

Does tirzepatide make birth control pills less effective?

It can. The Zepbound label says tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays stomach emptying, and it instructs patients on the pill to switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase. Non-oral methods are not affected.

Does semaglutide affect birth control?

Not in a clinically significant way, according to the Wegovy label, which reports no meaningful change in ethinyl estradiol or levonorgestrel levels when taken with semaglutide. No backup method is required by the label. If you vomit soon after taking a pill, your pill's own missed-dose rules apply.

Which birth control methods are not affected by GLP-1s?

Any method that does not go through the stomach: hormonal and copper IUDs, the implant, the vaginal ring, the patch, and the contraceptive injection. The Zepbound label states non-oral hormonal methods should not be affected. Condoms are the barrier method the label refers to.

How long before trying to get pregnant should I stop a GLP-1?

The Wegovy label says to stop semaglutide at least two months before a planned pregnancy because it leaves the body slowly. Tirzepatide's label does not give a lead time but says to stop when pregnancy is recognized. Both state that weight loss offers no benefit in pregnancy and may harm the fetus. Discuss timing with your clinician before starting.

Can I take semaglutide or tirzepatide while breastfeeding?

The data are limited. Tirzepatide's label reports undetectable or very low levels in breast milk but no data on infant effects; semaglutide's label says there are no data on its presence in human milk. Neither label clears it. Involve your clinician and your child's pediatrician in the decision.